Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Raphaël Clère-Jehl, Richard Greil et al.|The Lancet Infectious Diseases|2021Cited by 344
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study GroupPeter Borchmann, Andreas Engert, Heinz Haverkamp et al.|Journal of Clinical Oncology|2011Cited by 190
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F. Schlenk, Hartmut Döhner, Peter Paschka et al.|Journal of Clinical Oncology|2019Cited by 111
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsChristian Dittrich, Richard Greil|Investigational New Drugs|2014Cited by 18
Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding – a case reportMoritz Mirna, Uta C. Hoppe, Michael Lichtenauer et al.|Scottish Medical Journal|2019Cited by 5